Zoetis (NYSE: ZTS) CEO sells 20,000 shares under 10b5-1 plan
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Zoetis Inc. Chief Executive Officer Kristin C. Peck reported exercising stock options for 20,000 shares of Zoetis common stock at an exercise price of $41.83 per share on February 17, 2026. On the same day, she completed preplanned open‑market sales totaling 20,000 shares under a Rule 10b5‑1 trading plan.
The sales were split into 9,200 shares at a weighted average price of $126.4601 (with individual trades ranging from $126.01 to $126.98) and 10,800 shares at a weighted average price of $127.5492 (with trades from $127.01 to $127.56). Following these transactions, she directly held 101,337 shares of common stock and indirectly held 833.6435 common stock equivalents through the Zoetis 401(k) savings plan as of December 31, 2025, along with substantial remaining stock options.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 20,000 shares ($2,540,964)
Net Sell
8 txns
Insider
PECK KRISTIN C
Role
Chief Executive Officer
Sold
20,000 shs ($2.54M)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 20,000 | $0.00 | -- |
| Exercise | Common Stock | 20,000 | $41.83 | $837K |
| Sale | Common Stock | 9,200 | $126.4601 | $1.16M |
| Sale | Common Stock | 10,800 | $127.5492 | $1.38M |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option — 249,632 shares (Direct);
Common Stock — 121,337 shares (Direct);
Common Stock — 833.644 shares (Indirect, 401(k))
Footnotes (1)
- The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 12, 2025, including for the sale of up to 20,000 shares of Zoetis common stock between January 2, 2026 and February 18, 2026 upon the exercise of certain vested stock options that have an expiration date of February 18, 2026. The Price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.01 to $126.98, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The Price reported in Table I, Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.01 to $127.56, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Represents the common stock equivalents held in the Zoetis Inc. Savings Plan, a 401(k) plan, as of December 31, 2025. Stock options (right to buy Zoetis Inc. common stock) granted pursuant to the Zoetis Inc. 2013 Equity and Incentive Plan. 32,634 options granted February 14, 2017 at an exercise price of $55.02 per option; 24,642 options granted February 13, 2018 at an exercise price of $73.24 per option; 20,661 options granted February 12, 2019 at an exercise price of $87.51 per option; 55,866 options granted February 11, 2020 at an exercise price of $144.03 per option; 61,078 options granted February 10, 2021 at an exercise price of $160.62 per option; and 54,751 options granted February 8, 2022 at an exercise price of $201.30 per option. Each option vests on the third anniversary of the date of grant. Each option expires on the tenth anniversary of the date of grant. Stock options (right to buy Zoetis Inc. common stock) granted pursuant to the Zoetis Inc. Amended and Restated 2013 Equity and Incentive Plan. One-third of each option will vest on the first, second and third anniversaries of the date of grant, February 19, 2025. One-third of each option vests on the first, second and third anniversaries of the date of grant, February 6, 2024. One-third of each option vests on the first, second and third anniversaries of the date of grant, February 8, 2023.
FAQ
What insider transactions did Zoetis (ZTS) CEO Kristin Peck report?
Kristin Peck exercised 20,000 stock options and sold 20,000 Zoetis shares. On February 17, 2026 she converted options at $41.83 per share, then executed two open‑market sales of 9,200 and 10,800 shares at weighted average prices above $126 per share.
What stock options does the Zoetis (ZTS) CEO hold following the reported trades?
Following the exercise, 249,632 stock options remained from one grant group. She also held separate stock option positions of 84,711, 62,500, and 67,148 options, each with specified exercise prices, vesting schedules, and 10‑year expiration terms tied to their original grant dates.
What was the purpose of the exercised Zoetis (ZTS) stock options?
The options were exercised as part of a prearranged plan to sell shares. The 10b5‑1 trading plan contemplated selling up to 20,000 Zoetis common shares between January 2, 2026 and February 18, 2026, upon exercise of vested stock options expiring on February 18, 2026.